BackAcelrx Pharmaceuticals Overview

Acelrx Pharmaceuticals Long Term Debt

Latest long-term debt for ACRX: $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer average / median

Loading

Acelrx Pharmaceuticals Long Term Debt History

Loading

Acelrx Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Acelrx Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Acelrx Pharmaceuticals (ACRX) FAQ

Acelrx Pharmaceuticals (ACRX) currently reports a long-term debt of $0 as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Acelrx Pharmaceuticals's long-term debt history and peer comparisons.

Acelrx Pharmaceuticals's long-term debt changed from $0 to $0 (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acelrx Pharmaceuticals reported $0 in long-term debt as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Acelrx Pharmaceuticals, and consider following ACRX for alerts when major investors trade the stock.

Acelrx Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACRX with unrelated industries.